What are Personalized neoantigen vaccine drugs?

Personalized neoantigen vaccine drugs are pharmacologic agents that share a common mechanism (typically targeting Patient-specific tumor neoantigens). 1 are currently marketed, with 6 more in clinical development.

What are the marketed Personalized neoantigen vaccine drugs?

Marketed Personalized neoantigen vaccine drugs include aMIL.

Personalized neoantigen vaccine

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

1 marketed 5 in Phase 3 1 in Phase 1

This page covers all Personalized neoantigen vaccine drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Patient-specific tumor neoantigens, Patient-specific neoantigens; CTLA-4, Tumor antigens.

Targets

Patient-specific tumor neoantigens · Patient-specific neoantigens; CTLA-4 · Tumor antigens

Marketed (1)

aMIL · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Oncology
aMIL is a personalized neoantigen vaccine that trains the immune system to recognize and attack cancer cells expressing patient-specific tumor mutations.

Phase 3 pipeline (5)

IO102-IO103 · IO Biotech · Oncology
IO102-IO103 is a personalized neoantigen vaccine designed to activate the immune system against patient-specific tumor mutations.
PACMx5 · SWOG Cancer Research Network · Oncology
PACMx5 is a personalized neoantigen vaccine designed to stimulate the immune system to recognize and attack cancer cells expressing patient-specific tumor mutations.
IMA901 · Immatics Biotechnologies GmbH · Oncology
IMA901 is a personalized neoantigen vaccine that trains the immune system to recognize and attack cancer cells expressing patient-specific tumor mutations.
mRNA-1010 · ModernaTX, Inc. · Oncology
mRNA-1010 is a therapeutic cancer vaccine that encodes personalized tumor-associated neoantigens to stimulate the patient's immune system to recognize and attack cancer cells.
SK-PC-B70M · SK Chemicals Co., Ltd. · Oncology
SK-PC-B70M is a therapeutic cancer vaccine designed to stimulate immune responses against tumor-associated antigens.

Phase 1 pipeline (1)

APVAC1 vaccine plus Poly-ICLC and GM-CSF · Immatics Biotechnologies GmbH · Oncology
APVAC1 vaccine targets tumor antigens, Poly-ICLC is a Toll-like receptor 3 agonist, and GM-CSF is a granulocyte-macrophage colony-stimulating factor.

Patent intelligence

personalized neoantigen vaccine patent landscape — aggregated cliff calendar, attackable patents, originator estates